{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:45:59Z","timestamp":1776764759594,"version":"3.51.2"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/inf.0b013e31829f0a7e","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T12:22:12Z","timestamp":1371644532000},"page":"1245-1256","source":"Crossref","is-referenced-by-count":14,"title":["Comparing Haemophilus influenzae Type b Conjugate Vaccine Schedules"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicola","family":"Low","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelagh M.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne W. S.","family":"Rutjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahara A.","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"di Nisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pippa","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210202","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(08)70152-X","article-title":"Haemophilus influenzae type b conjugate vaccine use and effectiveness.","volume":"8","author":"Morris","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R2-20-20210202","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(09)61203-4","article-title":"Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates.","volume":"374","author":"Watt","year":"2009","journal-title":"Lancet"},{"key":"R5-20-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4161\/hv.6.10.13017","article-title":"Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries.","volume":"6","author":"Fitzwater","year":"2010","journal-title":"Hum Vaccin"},{"key":"R7-20-20210202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10096-006-0092-4","article-title":"Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis.","volume":"25","author":"Obonyo","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R8-20-20210202","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1017\/S0950268812000957","article-title":"Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials.","volume":"140","author":"Griffiths","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"suppl 1","key":"R9-20-20210202","doi-asserted-by":"crossref","first-page":"i172","DOI":"10.1093\/ije\/dyq033","article-title":"The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.","volume":"39","author":"Theodoratou","year":"2010","journal-title":"Int J Epidemiol"},{"key":"R11-20-20210202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials.","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"R12-20-20210202","doi-asserted-by":"crossref","first-page":"b3244","DOI":"10.1136\/bmj.b3244","article-title":"The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study.","volume":"339","author":"Nuesch","year":"2009","journal-title":"BMJ"},{"key":"R13-20-20210202","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/art.24894","article-title":"The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study.","volume":"61","author":"Nuesch","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R14-20-20210202","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R15-20-20210202","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R16-20-20210202","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0264-410X(98)00273-4","article-title":"Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey.","volume":"17","author":"Hoppenbrouwers","year":"1999","journal-title":"Vaccine"},{"key":"R17-20-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0264-410X(98)00232-1","article-title":"A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age.","volume":"17","author":"Scheifele","year":"1999","journal-title":"Vaccine"},{"key":"R18-20-20210202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/hv.1.5.2079","article-title":"Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age.","volume":"1","author":"Scheifele","year":"2005","journal-title":"Hum Vaccin"},{"key":"R19-20-20210202","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.inf.0000259955.66171.0c","article-title":"Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young children.","volume":"26","author":"Scheifele","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20-20210202","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(97)07456-4","article-title":"Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.","volume":"351","author":"Lagos","year":"1998","journal-title":"Lancet"},{"key":"R21-20-20210202","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00006454-199804000-00006","article-title":"Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.","volume":"17","author":"Lagos","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20-20210202","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1016\/j.vaccine.2011.09.131","article-title":"Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPVPRP approximately T vaccine compared to separate vaccines (DTaP, PRP approximately T and IPV) following primary vaccination of healthy infants in the Peoples Republic of China.","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"key":"R24-20-20210202","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"R26-20-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1542\/peds.86.1.102","article-title":"Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants.","volume":"86","author":"Campbell","year":"1990","journal-title":"Pediatrics"},{"key":"R27-20-20210202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/02724936.1994.11747715","article-title":"The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.","volume":"14","author":"Mulholland","year":"1994","journal-title":"Ann Trop Paediatr"},{"key":"R28-20-20210202","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.vaccine.2009.03.035","article-title":"Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status.","volume":"27","author":"Asturias","year":"2009","journal-title":"Vaccine"},{"key":"R30-20-20210202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4269\/ajtmh.1998.59.837","article-title":"Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger.","volume":"59","author":"Campagne","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"R31-20-20210202","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00006454-199811000-00013","article-title":"Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.","volume":"17","author":"Carlsson","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20-20210202","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.1995.03520350031024","article-title":"Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.","volume":"273","author":"Anderson","year":"1995","journal-title":"JAMA"},{"key":"R33-20-20210202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0022-3476(95)70545-7","article-title":"Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines.","volume":"126","author":"Lieberman","year":"1995","journal-title":"J Pediatr"},{"key":"R34-20-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1542\/peds.80.2.283","article-title":"Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants.","volume":"80","author":"Lenoir","year":"1987","journal-title":"Pediatrics"},{"key":"R36-20-20210202","first-page":"201","article-title":"Understanding controlled trials.","volume":"316","author":"Sibbald","year":"1998","journal-title":"Why are randomised controlled trials important BMJ"},{"key":"R37-20-20210202","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1016\/j.vaccine.2010.06.107","article-title":"Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review.","volume":"28","author":"OLoughlin","year":"2010","journal-title":"Vaccine"},{"key":"R38-20-20210202","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/INF.0b013e3182a14e57","article-title":"Effectiveness of Haemophilus influenzae type b (Hib) vaccines administered according to different schedules: systematic review and meta-analysis of observational data.","volume":"32","author":"Jackson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R39-20-20210202","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"R40-20-20210202","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199106203242503","article-title":"The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.","volume":"324","author":"Santosham","year":"1991","journal-title":"N Engl J Med"},{"key":"R41-20-20210202","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00006454-199603000-00008","article-title":"Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.","volume":"15","author":"Lagos","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R42-20-20210202","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(96)09267-7","article-title":"Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine corrected for prevention of pneumonia and meningitis in Gambian infants.","volume":"349","author":"Mulholland","year":"1997","journal-title":"Lancet"},{"key":"R43-20-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(04)17664-2","article-title":"Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial.","volume":"365","author":"Gessner","year":"2005","journal-title":"Lancet"},{"key":"R44-20-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199102000-00004","article-title":"Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.","volume":"10","author":"Black","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"R45-20-20210202","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis.","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"R46-20-20210202","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R47-20-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R48-20-20210202","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/CVI.00191-07","article-title":"Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy.","volume":"14","author":"Southern","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R49-20-20210202","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/adc.2007.126888","article-title":"Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign.","volume":"93","author":"Ladhani","year":"2008","journal-title":"Arch Dis Child"},{"issue":"suppl 9","key":"R50-20-20210202","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1097\/00006454-199809001-00026","article-title":"Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines.","volume":"17","author":"Slack","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R51-20-20210202","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0140-6736(03)13171-6","article-title":"Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.","volume":"361","author":"McVernon","year":"2003","journal-title":"Lancet"},{"key":"R52-20-20210202","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/adc.2006.097501","article-title":"Host and environmental factors associated with Hib in England, 1998-2002.","volume":"93","author":"McVernon","year":"2008","journal-title":"Arch Dis Child"},{"key":"R53-20-20210202","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e31829f0a7e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T19:11:46Z","timestamp":1645816306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201311000-00020"}},"subtitle":["A Systematic Review and Meta-analysis of Vaccine Trials"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31829f0a7e","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}